Role of YAP in lung cancer resistance to cisplatin

Yes-associated protein (YAP) serves a critical role in the initiation and progression of a variety of types of cancer via modulating the expression of genes involved in cell proliferation and the downregulation of apoptosis. Recent studies have suggested that YAP is responsible for the development o...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2018-09, Vol.16 (3), p.3949-3954
Main Authors: Song, Juan, Xie, Li-Xia, Zhang, Xin-Yi, Hu, Ping, Long, Mei-Fang, Xiong, Fang, Huang, Juan, Ye, Xiao-Qun
Format: Article
Language:English
Subjects:
Apoptosis
Cancer therapies
Care and treatment
Cell growth
Chemotherapy
Cisplatin
Development and progression
Drug resistance
Genetic aspects
Health aspects
Kinases
Liver cancer
Lung cancer
Metastasis
Oncology
Ovarian cancer
Patient outcomes
Proteins
Stem cells
Studies
Transcription factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Yes-associated protein (YAP) serves a critical role in the initiation and progression of a variety of types of cancer via modulating the expression of genes involved in cell proliferation and the downregulation of apoptosis. Recent studies have suggested that YAP is responsible for the development of drug resistance and cancer metastasis and recurrence. However, the association between YAP and chemoresistance in lung cancer, particularly in lung cancer stem cells (LCSCs) remains largely unknown. In the current study, lung cancer cell spheres were established using the A549 cell line, which demonstrated stem cell properties. It was revealed that YAP was overexpressed in lung cancer spheres compared with normal A549 adherent cells and was associated with enhanced cisplatin (CDDP) resistance. Knockdown of YAP effectively sensitized the adherent A549 and tumor spheres to CDDP treatment and resulted in enhanced cell death. These results suggest that YAP serves a critical role in LCSCs drug resistance and YAP targeting could become a promising adjuvant to current the chemotherapy for lung cancer.
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2018.9141